🔗 Share this article

As America proceeds with historic revisions to its immunization schedules, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus vaccinations during the global health crisis and has concentrated on alleged fatalities after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Schedule

Health officials were set to unveil sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US out of step with much of the international standard with no evidence for benefit. The planned update has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending specific childhood shot schedules in the US in order to be more like the Danish model, a society with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, head of the FDA’s CBER – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious track record in drug development, oversight or administrative roles, which has been customary for previous heads of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Former directors of the center would “grasp legal statutes and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that former directors who headed CBER have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner emphasized.

“The public just zeroes in on the novel medication approvals, but the generic program clears a multitude of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one have to be managed,” she said. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the job, which oversees over 5,000 employees. “It is a huge leadership role, if you perform it correctly,” Woodcock added.

Response and Controversial Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson said that the “questions stem from inaccurate premises”.

“Her experience matches the functions of her role,” the official said, pointing to the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a contentious one-day therapy clearance system that apparently troubled her former heads. “How are these drugs being chosen for this voucher program? Who takes the calls?” Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer regulations of most medications, except for immunizations.”

Public History on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, track record, critics said. She authored a research paper using non-validated crowd-sourced reports to assess the frequency of heart inflammation following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are riskier than they are.

Among her “desired changes” for the new federal leadership encompassed changing rules for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has allegedly suggested excluding teenage boys from getting Covid vaccinations.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|